Introduction
============

The availability of non-invasive mechanical ventilation (NIMV) as a treatment choice for chronic hypercapnic respiratory failure (CHRF), and the improved survival in many diseases as a consequence of this treatment, has led to a large increase in the number of patients using home NIMV.[@b1-copd-10-2559] Home NIMV is an effective treatment method for the management of CHRF, particularly in patients with chest wall and neuromuscular disorders.[@b2-copd-10-2559] Furthermore, in recent decades, NIMV has been used effectively in the treatment of other diseases that cause CHRF, such as obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease (COPD).[@b3-copd-10-2559],[@b4-copd-10-2559]

The impact of COPD and CHRF on patients' well-being is mainly manifested as a reduction in lung function capacity following daily activities.[@b5-copd-10-2559] Studies have shown discordant results on the benefits of NIMV with respect to quality of life, regardless of the underlying cause of CHRF.[@b6-copd-10-2559]--[@b8-copd-10-2559] Being a cheap, reproducible, and easily standardizable test providing a non-specific, but holistic assessment of exercise capacity, the 6-minute walking test (6MWT) is often used in clinical practice, in addition to the symptom scales and primary pulmonary function tests, such as spirometry and arterial blood gas (ABG) analysis.[@b9-copd-10-2559] The test is well tolerated, cost-effective, and does not require sophisticated equipment to perform. The 6-minute walking distance (6MWD) has been used as an outcome parameter in determining the efficacy of NIMV in both COPD and restrictive diseases.[@b7-copd-10-2559],[@b10-copd-10-2559] In the present study, we aimed to evaluate exercise capacity among patients with CHRF secondary to COPD and other etiologies, and the impact of NIMV use at home. We used 1-year follow-up data on 6MWT performance relative to the underlying diagnoses.

Methods
=======

Study population
----------------

A total of 105 consecutive patients with CHRF who received NIMV treatment during their intensive care unit (ICU) hospitalization, and home NIMV post-discharge, were included in this retrospective study conducted from January 2011 to January 2012. Patients who received NIMV in the ICU, or at home for at least 4 hours per day, including nocturnal NIMV, and who attended the first follow-up visit 1 month after discharge and who completed a 1-year post-discharge follow-up at the respiratory intensive care outpatient clinic, were included in the study. These patients had not received NIMV prior to their ICU stay. Patients who were disabled or unwilling to walk, as well as patients with clinical signs of airway infection, current exacerbations, or unstable cardiac arrhythmia, were excluded. A consort diagram showing patient enrollment and study flow is presented in [Figure 1](#f1-copd-10-2559){ref-type="fig"}.

The ethics committee of Kartal Teaching and Research Hospital, Istanbul, Turkey, approved this study, which was conducted in accordance with the Declaration of Helsinki (No 89513307/1009/427, Date March 26, 2015). It was designed as a retrospective cohort study in a large, pulmonary disease-based, tertiary training and research hospital in Istanbul, Turkey.

Etiologies of CHRF
------------------

Subjects who had no exacerbation episode, nor increased need for ongoing medical treatment and no findings suggestive of acidosis in ABG analysis in 4 weeks prior to the study or measurement were considered to be clinically stable. Subjects in a stable clinical condition were grouped according to their underlying diagnosis as COPD (n=37), OHS (n=34), kyphoscoliosis (KS, n=20), and diffuse parenchymal lung disease (DPLD, n=14).

The diagnosis of COPD was based on clinical history, symptoms, and airway obstruction (ie, forced expiratory volume in 1 second \[FEV~1~\]/forced vital capacity \[FVC\] \<70% of predicted after bronchodilator inhalation).[@b11-copd-10-2559] OHS was defined by a body mass index (BMI) \>30 kg/m^2^, daytime partial carbon dioxide pressure (PaCO~2~) ≥45 mmHg prior to NIMV therapy, and clinical symptoms of CHRF in the absence of other known causes of hypoventilation.[@b12-copd-10-2559] DPLD was defined as lung parenchyma defective due to tuberculosis sequels or bronchiectasis, which caused hypoventilation and resulted in hypoxemia and hypercapnia.

Study procedures
----------------

Demographic data, respiratory symptoms, BMI, and a history of long-term oxygen therapy (LTOT) were recorded retrospectively from our outpatient clinic patient files. Individuals' self-reported comorbidities, as assessed by the Charlson index,[@b13-copd-10-2559] which assigns each disease with a score that is proportional to the disease-related risk of death, were retrieved from the medical files. The Charlson index was computed during the hospital stay by the physician in charge of each admitted patient.

6MWTs were performed twice; once at baseline (1 month after discharge) and once after a 12-month interval, by the same physical therapist. ABG analyses and spirometry performed at the same time points of the 6MWTs were recorded. Data recorded at emergency admission, during the hospital stay and in the interval between the last exacerbation and the 1-year assessment, were evaluated in patients with CHRF relative to their underlying diagnoses. Also, demographic and clinical (baseline and 1-year values for BMI \[kg/m^2^\], FEV~1~ \[mL\], partial carbon dioxide pressure in arterial blood gas analysis \[PCO~2~\] \[mmHg\], 6MWD \[m\], and difference between first and second 6-minute distance with 1-year interval \[Δ6MWD\]) characteristics of COPD patients were analyzed relative to the presence vs absence of emergency or hospital admission. Pre-test and post-test scores for dyspnea and fatigue at the 1-month and 1-year post-discharge 6MWT were also evaluated in the study groups.

Ideal 6MWT results for all patients were calculated according to the formula described earlier and presented in meters as 6MWD, predicted 6MWD, and predicted percentage 6MWD. Pre- and post-test heart rate, pH, PaCO~2~, partial oxygen pressure (PaO~2~), blood bicarbonate (HCO~3~) concentration, PaO~2~/fraction of inspired oxygen (FiO~2~), FEV~1~ (mL and %), FVC (mL and %), and FEV~1~/FVC measurements were also recorded from the medical files. Differences between the results of the two analyses performed 1 year apart for each parameter (delta values) were calculated.

6-Minute walking test
---------------------

The 6MWD was determined based on the American Thoracic Society guidelines, while the subjects had their usual oxygen flow.[@b9-copd-10-2559] The test was performed in a 30-m long corridor by a physical therapist with specific experience. Two traffic cones demarcated the course, and the corridor was marked every 3 m. Instructions and verbal encouragement given to the subjects were standardized. Encouragement was given every minute during the test until subject exhaustion. The end of the test was determined, either by the subject for any reason, or by the physical therapist conducting the test. Chest pain, intolerable dyspnea, dizziness, leg cramps, diaphoresis, and pallor were additional criteria for immediately stopping the test. The Borg dyspnea scale[@b14-copd-10-2559] and Visual Analog Scale to Evaluate Fatigue Severity (VAS-F)[@b15-copd-10-2559] were used to determine fatigue and dyspnea scores, respectively, as described. Heart rate was measured before and throughout the 6MWT, with the values recorded at the end of each minute during the test. Oxygen saturation was recorded before, and was monitored continuously during the 6MWT, with the tester walking behind the patient. Reference equations, both actual and as a percent-of-predicted 6MWD, are known to be important for assessing cardiopulmonary function.[@b16-copd-10-2559] Ideal 6MWD values were calculated according to a formula, and by using the reference equations provided by Enright and Sherrill.[@b17-copd-10-2559] The test results were recorded as ideal \[1,140 − (5.61× BMI) − (6.94× age) for males and 1,017 − (6.24× BMI) − (5.83× age) for females\], percent-of-predicted (% of ideal 6MWD), and lower limit of normal values (ideal 6MWD − 153 m for males and ideal 6MWD − 139 m for females), according to previous methods.

Home NIMV
---------

Home NIMV devices were prescribed according to home mechanical ventilation guidelines after a good response was achieved with NIMV during the ICU stay.[@b18-copd-10-2559] All patients had home NIMV via a bi-level positive airway pressure (BiPAP) machine in a spontaneous/timed (S/T) mode with an oronasal interface. Treatment efficacy was assessed by clinical status and ABG measurements. Inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) values of NIMV devices were titrated and recorded. A specialized NIMV nurse also measured objective NIMV usage at every outpatient clinic visit by checking the built-in time counter of the NIMV device. The IPAP was titrated during ventilation in steps of 1 mbar/min to achieve the desired tidal volume, and was set between the EPAP and 30 mbar. Therapy hours of NIMV devices were noted in each control by the same nurse.

BMI calculation
---------------

BMI was calculated and documented. For KS subjects, height was calculated from arm span (largest distance across the middle fingers when the arms were outstretched horizontally). In males, arm span/1.03 m, and in women, arm span/1.01 m, was used for standing height in the regression equation.[@b19-copd-10-2559]

ABG analysis
------------

On the day of the outpatient clinic visit, ABG's (Rapidlab, Bayer, Leverkusen, Germany) were analyzed at rest from the radial artery. Samples were taken in the daytime during spontaneous breathing of room air, if possible, or during the subject's usual oxygen flow. Oxygenation was defined as PaO~2~/FiO~2~. Spirometry (Zan GPI 3.00, nSpire Health, Longmont, CO, USA) was performed according to the American Thoracic Society guidelines.[@b20-copd-10-2559]

Statistical analysis
--------------------

Data were analyzed using the Statistical Package for Social Sciences, version 15.0 (SPSS 15.0, SPSS, Chicago, IL, USA). The chi-square (*χ*^2^) test was used for the comparison of categorical data. Numerical data were analyzed using the independent sample *t*-test and one-way analysis of variance (ANOVA) for variables with normal distribution, while the Kruskal--Wallis test was used for non-normal distributed variables. Linear regression analysis, including age, sex, basal measurements of 6MWD, FEV~1~, PaCO~2~, and diagnostic groups, was performed. Data were expressed as the mean ± standard deviation (SD), percentage (%), median (percentile 25--75), and 95% confidence interval (CI, min to max), where appropriate. A *P*-value \<0.05 was considered significant.

Results
=======

Among the 105 patients who completed the 1-year follow-up, mean ± SD age was 61±12 years, and 30.5% were female. Thirty-seven patients had COPD, 34 had OHS, 20 patients had KS, and 14 had DPLD. Baseline characteristics of the study groups are shown in [Table 1](#t1-copd-10-2559){ref-type="table"}.

The mean ± SD BMI was 41±6 kg/m^2^ in the OHS group, while it was within normal limits in the other groups ([Table 1](#t1-copd-10-2559){ref-type="table"}). All patients had a history of LTOT. Among the comorbidities, arthropathy or joint prostheses that may interfere with the 6MWT were present in only 2 (5.4%) patients with COPD, 1 (5.0%) patient with KS, 2 (14.3%) patients with DPLD, and 31 (91.2%) patients with OHS.

The 6MWD increased in the COPD, KS, and DPLD patients after 1 year, and this was significant in the KS and DPLD groups. It decreased in the OHS group with a change of −13.9 m (95% CI −31.9 to 3.96) ([Table 2](#t2-copd-10-2559){ref-type="table"}). The number of patients with a Δ6MWD ≥30 m was 11 (29.7%), 8 (23.5%), 12 (60.0%), and 7 (50.0%) in the COPD, OHS, KS, and DPLD patients, respectively.

There were no statistically significant differences between groups in the baseline and delta values of pH, PCO~2~, PaO~2~, HCO~3~, PaO~2~/FiO~2~ ratio, FEV~1~ (mL), FEV~1~%, FVC (mL), FVC%, and FEV~1~/FVC ([Table 3](#t3-copd-10-2559){ref-type="table"}).

The baseline and delta values after 1 year of 6MWD and predicted percentage of 6MWD were significantly different between the four groups, as shown in [Table 2](#t2-copd-10-2559){ref-type="table"} and [Figure 2](#f2-copd-10-2559){ref-type="fig"}. The OHS group had the lowest baseline 6MWD, which decreased over time, while the KS group had the best baseline values, and the greatest improvement.

COPD patients had significantly higher post-test scores for dyspnea noted during the 1-year 6MWT compared with patients with other underlying diagnoses \[median 3 (1--5) vs 1 (0--2) for each other diagnosis, *P*=0.003\]. However, no other significant differences were noted between the diagnostic groups in terms of pre- and post-test VAS-F and dyspnea scores during the baseline and 1-year 6MWT ([Table 4](#t4-copd-10-2559){ref-type="table"}).

No significant difference was noted in terms of emergency admission, hospital stay, and the interval between the last exacerbation and 1-year assessment in the patients who were clinically stable but with different underlying diagnoses. While OHS patients had significantly higher mean ± SD values for BMI during the 1-month and 1-year measurements (*P*=0.001 for each), no significant change was detected in ΔBMI from the 1-month to 1-year measurement between the study groups ([Table 5](#t5-copd-10-2559){ref-type="table"}).

No significant difference was noted in demographic characteristics as well as mean ± SD baseline and 1-year values for BMI (kg/m^2^), FEV~1~ (mL), PCO~2~ (mmHg), and 6MWD (m) among COPD patients with respect to the presence of emergency or hospital admission ([Table 6](#t6-copd-10-2559){ref-type="table"}).

We used linear regression analyses to adjust the change in 6MWD for age, sex, baseline 6MWD, baseline FEV~1~, and baseline PaCO~2~ values, and the disease groups were compared with the COPD group (as the reference group). [Table 7](#t7-copd-10-2559){ref-type="table"} shows that OHS is a significant negative predictor factor for an improvement in 6MWD (linear regression coefficient −24.48; *P*=0.048), indicating that a lower increase in 6MWD is expected in OHS patients compared with COPD patients. Likewise, patients with a higher baseline 6MWD are candidates for a lesser improvement in the distance after 1 year with home NIMV (linear regression coefficient −0.16; *P*=0.003).

Discussion
==========

The present study showed that after 1 year, exercise capacity, as assessed by a change in the 6MWD, varied according to the etiology of CHRF in patients under home NIMV treatment. We showed a small, non-significant increase in this distance in COPD patients, a significant improvement in KS and DPLD patients, and no improvement, even a worsening (although not significant), in OHS patients.

The efficacy of NIMV treatment for acute respiratory failure due to COPD exacerbation has been well proven. It reduces hospital deaths and complications associated with treatment, and length of hospital stay.[@b21-copd-10-2559] However, studies and systematic reviews on the effects of chronic NIMV in stable hypercapnic COPD are controversial.[@b22-copd-10-2559] Several randomized controlled trials failed to show a clear benefit of home NIMV on lung function, gas exchange, sleep efficiency, and health-related outcomes in the treatment of stable COPD.[@b23-copd-10-2559],[@b24-copd-10-2559] The 6MWT was used as the pulmonary function test to evaluate treatment response in these studies, particularly in those conducted in the 2000s. In a recent randomized study by Funk et al, COPD patients remaining hypercapnic after an acute respiratory failure attack were shown to potentially benefit from long-term NIMV based on improved 6MWD. They also had a higher probability of experiencing clinical deterioration after withdrawal of the NIMV treatment.[@b25-copd-10-2559]

Being standardized in terms of disease severity, treatment, and performing the tests, the minimum clinically relevant difference in 6MWD for chronic respiratory diseases has been considered to be 30 m.[@b26-copd-10-2559] Among our 37 COPD patients only 11 (29.7%) demonstrated this level of 6MWD improvement, which emphasizes the need for larger scale studies for more accurate estimations.

Pinto-Plata et al have investigated the relationship between Δ6MWD and mortality among severe COPD patients for a minimum of a 1-year period.[@b27-copd-10-2559] Their prospective study showed that 6MWD declined progressively over time and it was a better predictor of mortality than FEV~1~, BMI, and associated comorbidities. Interestingly, they showed an average decline of 26 m in 1 year, whereas our COPD patients had a mean increase of 10.4 m. Although in the study of Pinto-Plata et al, a history of ICU stay, use of LTOT or home NIMV, ABG analysis, and degree of chronic respiratory failure were not specified, average values reported for basal FEV~1~ (1.04±0.39 L) and 6MWD (238±107 m) were worse than identified in our cohort (0.66±0.26 L and 332±99 m, respectively).[@b27-copd-10-2559] Therefore, while a more favorable outcome (in terms of 6MWD) identified in our COPD patients may indicate the positive effect of home NIMV on exercise capacity, the likely impact of differences in methodology, disease severity, and patient characteristics on the discrepancy in findings should also be noted.

Nevertheless, given that the four diagnostic groups were homogenous in terms of emergency admission, hospital stay and the interval between the last exacerbation and 1-year assessment, our findings would seem relevant considering the impact of home NIMV on exercise capacity in different etiologies of CHRF in the clinical practice.

In a study by De Backer et al,[@b28-copd-10-2559] COPD patients remaining chronically hypercapnic after an acute exacerbation were reported to be treated effectively with home NIMV via enabling greater airflow in better functioning parts of the lung with preserved blood flow, which led to better ventilation/perfusion and improved exercise capacity. This improvement in the distribution of airflow may be affected by the relationship between the level of applied inspiratory pressure and the recruitment of the peripheral airways. In a recent systematic review and individual patient data meta-analysis regarding NIMV in stable COPD, significantly improved gas exchange results were reported to be achieved during the day, and consequently better exercise capacity was associated with an IPAP cut-off point of 18 cm H~2~O.[@b29-copd-10-2559] Given that no significant difference was noted in demographic characteristics as well as baseline and 1-year values for BMI (kg/m^2^), FEV~1~ (mL), PCO~2~ (mmHg), and 6MWD (m) among COPD patients with respect to the presence of emergency or hospital admission in our study, the increase in 6MWD of COPD patients in 1 year under home NIMV may be due to the relatively higher IPAP values (24 cm H~2~O).

Home NIMV therapy has been associated with a decline in outpatient admission and hospitalization rates,[@b30-copd-10-2559] as well as better survival with long-term use[@b31-copd-10-2559] in patients with OHS. Also, the addition of long-term NIMV, targeted to greatly reduce hypercapnia, to standard treatment has been shown to be associated with improved survival among patients with hypercapnic stable COPD.[@b32-copd-10-2559]

However, there have been limited studies on changes in 6MWD during long-term home NIMV therapy. Castro-Añón et al investigated the impact of home NIMV treatment by assessing 6MWT among 20 patients with OHS.[@b33-copd-10-2559] With a greater mean baseline 6MWD than identified in our cohort (350±110 m), the authors reported a significant increase in the distance after 6 months of home NIMV. Interestingly, a decrease in 6MWD was noted in our OHS patients, despite no significant increase in BMI values in 1 year in this group of patients. These contradictory results may be attributed to differences in sample size, disease severity (as revealed by baseline 6MWD), and a history of recent discharge from the ICU, as well as the duration of follow-up. Although Castro-Añón et al did not report on the presence of any disabilities or comorbidities, these might have affected 6MWD if present.[@b33-copd-10-2559] The presence of arthropathy or joint prostheses as comorbidities in the majority of our patients with OHS should also be considered when evaluating the lack of improvement in 6MWD. Enright and Sherrill reported that the 6MWT results were affected by the degree of musculoskeletal mobility and aerobic capacity.[@b17-copd-10-2559] Donini et al demonstrated that the presence of a disability, as evaluated by the obesity-related disability test (*Test SIO Disabilità Obesità Correlata*; TSD-OC), significantly decreased 6MWD.[@b34-copd-10-2559] NIMV treatment improves clinical symptoms, diurnal oxygenation, and respiratory muscle performance in KS patients.[@b35-copd-10-2559] Fuschillo et al conducted a study with six KS patients and showed that a 1-week course of nocturnal NIMV significantly increased 6MWD.[@b36-copd-10-2559] Despite the differences in the sample size (6 vs 20), the duration of follow-up (7 days vs 1 year), and the basal 6MWD (244.7±132.2 vs 373 m), our study also revealed a significant increase in 6MWD in the KS patients (*P*=0.004). However, this finding proved insignificant in comparison to the mean difference in COPD patients, possibly due to the disparity between the number of subjects in the COPD and KS groups.

The mean Δ6MWD in the DPLD group did not differ significantly compared to the COPD patients. Home NIMV treatment of patients with tuberculosis sequelae reportedly increases survival with LTOT.[@b37-copd-10-2559] The effect of home NIMV and pulmonary rehabilitation on 6MWT among patients with tuberculosis sequelae was evaluated in two different studies, and it was shown that these patients had the same degree of significant change compared to patients with COPD; consistent with our results.[@b38-copd-10-2559],[@b39-copd-10-2559] To our knowledge, the only study that compared 6MWD in two different cohorts with different diagnoses, including bronchiectasis and COPD causing CHRF, is the study of Jenkins and Cecins.[@b40-copd-10-2559] In this study, the authors found that the 6MWD of patients with bronchiectasis had a statistically smaller increase compared with COPD patients. However, in addition to the fact that they were not ICU patients, the sample size distribution between the groups was markedly different (COPD, n=245; bronchiectasis, n=33).

There are several limitations that need to be addressed. The most important limitation is the retrospective, non-randomized design of the study. This makes it difficult to speculate on the specific effects of home NIMV on 6MWD, due to the lack of data on parameters including adherence to home NIMV treatment and level of ventilation control. However, it should be noted that considering the large consensus that home NIMV is an effective treatment for CHRF, ethical issues to be raised by constituting a randomized controlled design whereby one of the groups would not receive home NIMV treatment would outweigh its potential research value. Second, we did not have the opportunity to observe the effects of pulmonary rehabilitation, as we did not have a pulmonary rehabilitation center at the time the study was conducted. Third, given that most OHS patients have obstructive sleep apnea that requires frequently elevated EPAP to maintain the patency of upper airway during sleep, lack of data on sleep tests, and thus sleep quality of patients with OHS, seems to be another limitation. These data would extend the knowledge achieved in the current study. Finally, the number of patients recruited in the diagnosis groups may not be sufficient to observe a significant difference between groups. However, there are no studies that we know of that have examined and compared the value of the 6MWT in assessing patients receiving home NIMV for the treatment of chronic respiratory failure due to different etiologies, at the same time and for such a long period.

In conclusion, our data demonstrated that exercise capacity, as measured by the 6MWD, in CHRF patients receiving long-term home NIMV treatment, depends on the etiological diagnosis. The 6MWD stands out as the only parameter that is progressively influenced in the COPD, KS, and DPLD subgroups of CHRF patients receiving home NIMV over a 1-year period. Clinicians should keep in mind that home NIMV therapy may have a favorable effect on exercise capacity in CHRF patients that can be tested with the 6MWT, without any apparent change in spirometry and ABG findings. Although OHS patients showed a decrease in 6MWD, this is thought to be related to their disability and a permanently high BMI, and these patients should be undergoing physical therapy rehabilitation and a strict diet, additional to home NIMV, to increase the benefit of home NIMV.
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###### 

Baseline characteristics of chronic respiratory failure patients having non-invasive ventilation at home followed at the outpatient clinic between 2011 and 2012

                                          COPD, n=37   OHS, n=34   Kyphoscoliosis, n=20   DPLD, n=14
  --------------------------------------- ------------ ----------- ---------------------- ------------
  Age, years, mean ± SD                   65±10        65±8        46±10                  62±12
  Female, %                               8.1          50          45                     21.4
  BMI, kg/m^2^, mean ± SD                 25±6         41±6        27±7                   27±6
  HNIV parameters, mean ± SD                                                              
   IPAP, cm H~2~O                         24±3         23±3        22±5                   21±5
   EPAP, cm H~2~O                         5.3±0.7      5.8±0.8     5.3±0.6                5.5±0.7
   Therapy duration, hour/day             6.7±1.9      6.4±2.4     5.9±1.8                5.8±1.4
  Charlson comorbidity index, mean ± SD   4±1          4±1         2±2                    3±1

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive lung disease; DPLD, diffuse parenchymal lung disease; EPAP, expiratory positive airway pressure; HNIV, home non-invasive ventilation; IPAP, inspiratory positive airway pressure; OHS, obesity hypoventilation syndrome; SD, standard deviation.

###### 

Baseline measurements and 1-year change in 6-minute walking test in chronic respiratory failure patients having non-invasive mechanical ventilation

                                                             COPD, n=37   OHS, n=34   Kyphoscoliosis (KS), n =20   DPLD, n=14   *P*-value[\*](#tfn4-copd-10-2559){ref-type="table-fn"}                                                                                             
  ---------------------------------------------------------- ------------ ----------- ---------------------------- ------------ -------------------------------------------------------- ----------------- --------- ------- ---------------- ----------- ------- ---------------- ------
  6MWD,[a](#tfn2-copd-10-2559){ref-type="table-fn"} m        332±99       10.43       −4.3 to 25.2                 315±74       −13.9                                                    −31.9 to 3.96     373±90    47.25   15.66--78.83     354±76      25.5    6.34--44.65      0.01
  Ideal 6MWD, m                                              550±100      −6.04       −22.02 to 9.92               418±77       −8.84                                                    −13.26 to −4.41   628±93    −5.4    −9.17 to−1.64    542±100     −9.86   −14.3 to −5.37   0.95
  Predicted,[b](#tfn3-copd-10-2559){ref-type="table-fn"} %   61.3±15.9    1.09        −1.55 to 3.73                75.7±14.5    −2.39                                                    −6.48 to 1.69     61.2±17   7.55    3.31 to 11.79    67.1±17.3   6.1     2.27--9.93       0.01
  LLN, m                                                     398±15.9     −0.83       −20.36 to 18.7               272±71       −10.31                                                   −16.14 to −4.47   482±92    −5.9    −9.65 to −2.16   392±98      −9.64   −14.3 to −4.96   0.71

**Notes:**

Baseline vs 1-year values: *P*=0.11 for COPD; *P*=0.21 for OHS; *P*=0.004 for KS; *P*=0.03 for DPLD, via paired Wilcoxon test.

Baseline vs 1-year values: *P*=0.23 for COPD; *P*=0.38 for OHS; *P*=0.003 for KS; *P*=0.01 for DPLD, via paired Wilcoxon test.

*P*-values for the comparison of mean Δ values among groups with different diagnoses. Significant for 6MWD upon post hoc Tukey HSD: KS vs COPD (*P*=0.049) and KS vs OHS (*P*\<0.001). Significant for predicted % upon post hoc Tukey HSD: OHS vs KS (*P*=0.002) and OHS vs DPLD (*P*=0.027).

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive lung disease; DPLD, diffuse parenchymal lung disease; HSD, honesty of significance difference; LLN, lower limit of normal range; OHS, obesity hypoventilation syndrome; SD, standard deviation; Δ, change; 6MWD, 6-minute walking distance.

###### 

Pulmonary function testing and arterial blood gas measurements in chronic respiratory failure patients having non-invasive mechanical ventilation

                  COPD, n=37   OHS, n=34   Kyphoscoliosis, n =20   DPLD, n=14   *P*-value[\*](#tfn6-copd-10-2559){ref-type="table-fn"}                                                                                                         
  --------------- ------------ ----------- ----------------------- ------------ -------------------------------------------------------- ------------------ ----------- --------- ------------------- ----------- -------- ------------------- ------
  pH              7.42±0.05    −0.03       −0.05 to −0.007         7.44±0.04    −0.002                                                   −0.04 to 0.004     7.45±0.05   −0.017    −0.04 to 0.012      7.43±0.05   −0.011   −0.04 to 0.02       0.76
  PaCO~2~, mmHg   49±8         0.56        −0.52 to 4.23           46±8         1.85                                                     −0.52 to 4.23      52±11       −2.85     −8.08 to 2.38       49±8        0.01     −5.7 to 5.7         0.27
  PaO~2~/FiO~2~   264±107      25.77       −11.36 to 62.91         287±58       17.93                                                    −5.98 to 41.84     300±85      14.20     −26.04 to 54.45     277±81      38.37    −0.47 to 77.22      0.76
  HCO~3~, mmol    31.5±5.8     −2.68       −4.85 to −0.71          31.3±5.6     −0.57                                                    −2.63 to 1.47      36.5±13.8   −5.88     −12.7 to 1.15       31.8±4.3    −0.55    −4.58 to 3.48       0.14
  SpO~2~%         89±8         2.48        0.2 to 4.76             92±3         0.41                                                     −0.8 to 1.63       92±4        −0.65     −7.81 to 6.51       92±4        2.42     0.23 to 4.62        0.46
  FEV~1~, mL      661±257      78.7        −12.04 to 169.54        1,133±645    −82.27                                                   −192.94 to 28.39   858±516     −21.6     −70.36 to 113.69    890±402     −25.7    −182.1 to 130.67    0.11
  FEV~1~, %       27±11        1.78        −1 to 4.56              50±20        −2.38                                                    −7.59 to 2.86      25±8        3.58      −1.51 to 8.68       34±15       0.14     −6.55 to 6.83       0.31
  FVC, mL         1,184±459    −52.18      −189.88 to 85.5         1,461±725    −138.63                                                  −283.24 to 5.97    1,018±609   −140.83   −487.42 to 205.76   1,113±504   60       −159.96 to 279.98   0.46
  FVC, %          37±14        −0.5        −4.58 to 3.58           52±18        11.13                                                    −21.29 to 43.57    24±7        3.08      −2.24 to 8.41       34±15       2.78     −4.85 to 10.42      0.76
  FEV~1~/FVC      68±21        0.4         −4.94 to 5.75           77±13        1.77                                                     −1.66 to 5.20      92±18       0.83      −4.07 to 5.73       80±10       −4.92    −13.06 to 3.2       0.42

**Note:**

*P*-values for the comparison of mean Δ values among groups with different diagnoses by ANOVA test.

**Abbreviations:** COPD, chronic obstructive lung disease; DPLD, diffuse parenchymal lung disease; FEV~1~, forced expiratory volume in 1 second; FiO~2~, fraction of inspired oxygen; FVC, forced vital capacity; HCO~3~, bicarbonate; OHS, obesity hypoventilation syndrome; PaCO~2~, partial carbon dioxide pressure; PaO~2~, partial oxygen pressure; SpO~2~, oxygen saturation; ANOVA, analysis of variance; CI, confidence interval; SD, standard deviation; Δ, change.

###### 

Pre-test and post-test scores for dyspnea and fatigue at baseline and 1-year 6MWT in study groups

                                                               COPD, n=37   OHS, n=34   Kyphoscoliosis, n=20   DPLD, n=14   *P*-value[\*](#tfn10-copd-10-2559){ref-type="table-fn"}
  ------------------------------------------------------------ ------------ ----------- ---------------------- ------------ ---------------------------------------------------------
  **Post-discharge 6MWT**                                                                                                   
  Baseline                                                                                                                  
   Dyspnea score[a](#tfn9-copd-10-2559){ref-type="table-fn"}                                                                
    Pre-test                                                   1 (1--2)     1 (0--2)    0 (0--1)               2 (0--2)     0.18
    Post-test                                                  2 (1--3)     2 (0--4)    1 (1--3)               2 (1--3)     0.67
   VAS-F score[a](#tfn9-copd-10-2559){ref-type="table-fn"}                                                                  
    Pre-test                                                   1 (0--2)     1 (0--2)    0 (0--1)               0 (0--2)     0.50
    Post-test                                                  2 (0--3)     2 (1--3)    1 (0--3)               1 (0--3)     0.30
  1-year                                                                                                                    
   Dyspnea score                                                                                                            
    Pre-test                                                   1 (0--2)     1 (0--2)    0 (0--1)               1 (0--1)     0.80
    Post-test                                                  3 (1--5)     1 (0--2)    1 (0--2)               1 (0--2)     0.003
   VAS-F score                                                                                                              
    Pre-test                                                   0 (0--2)     0 (0--2)    0 (0--1)               0 (0--1)     0.527
    Post-test                                                  1 (0--3)     1 (0--2)    1 (0--2)               1 (0--1)     0.442

**Notes:** Data are shown as median (25th--75th percentile).

Dyspnea and fatigue scores may be between 0 and 10. Higher scores indicate higher severity.

Kruskal-- Wallis test.

**Abbreviations:** COPD, chronic obstructive lung disease; DPLD, diffuse parenchymal lung disease; OHS, obesity hypoventilation syndrome; VAS-F, Visual Analog Scale to Evaluate Fatigue Severity; 6MWT, 6-minute walking test.

###### 

Data on body mass index alteration, emergency admission, hospital stay, and the interval between last exacerbation and 1-year assessment in study groups

                                                                COPD, n=37   OHS, n=34    Kyphoscoliosis, n=20   DPLD, n=14   *P*-value
  ------------------------------------------------------------- ------------ ------------ ---------------------- ------------ ----------------------------------------------------
  Body mass index (kg/m^2^)                                                                                                   
   Baseline, mean ± SD                                          25.0±6.0     41.0±6.0     27.0±7.0               27.0±6.0     0.001[a](#tfn12-copd-10-2559){ref-type="table-fn"}
   1-year, mean ± SD                                            26.0±6.0     42.0±6.0     28.0±7.0               28.0±6.0     0.001[a](#tfn12-copd-10-2559){ref-type="table-fn"}
   Δ, mean ± SD                                                 0.0±2.0      0.0±2.0      0.0±2.0                1.0±1.0      0.96[a](#tfn12-copd-10-2559){ref-type="table-fn"}
  Emergency admission                                                                                                         
   Present, n (%)                                               18 (17.1)    13 (12.4)    5 (4.8)                4 (3.8)      0.298[b](#tfn13-copd-10-2559){ref-type="table-fn"}
   Number of admissions, mean ± SD                              2.0±1.0      2.0±1.0      1.0±0.0                2.0±1.0      0.312[a](#tfn12-copd-10-2559){ref-type="table-fn"}
  Hospital stay                                                                                                               
   Present, n (%)                                               12 (11.4)    4 (3.8)      2 (1.9)                2 (1.9)      0.081[b](#tfn13-copd-10-2559){ref-type="table-fn"}
   Number of hospitalizations, mean ± SD                        2.0±1.0      2.0±0.0      1.0±0.0                2.0±1.0      0.698[a](#tfn12-copd-10-2559){ref-type="table-fn"}
   Length of stay (days), mean ± SD                             10.0±5.0     11.0±3.0     7.0±3.0                10.0±4.0     0.839[a](#tfn12-copd-10-2559){ref-type="table-fn"}
  Days from last exacerbation to 1-year assessment, mean ± SD   204.0±50.0   210.0±52.0   260.0±13.0             234.0±61.0   0.134[a](#tfn12-copd-10-2559){ref-type="table-fn"}

**Notes:**

ANOVA test.

*χ*^2^ test.

**Abbreviations:** COPD, chronic obstructive lung disease; DPLD, diffuse parenchymal lung disease; OHS, obesity hypoventilation syndrome; SD, standard deviation; Δ, change; ANOVA, analysis of variance.

###### 

Demographic and clinical characteristics of patients with COPD according to the presence of emergency or hospital admission

                              COPD (n=37)                                                                                                 
  --------------------------- ------------- ------------- ---------------------------------------------------- ------------ ------------- ---------------------------------------------------
  Age (years), mean ± SD      63±10         66±10         0.34[a](#tfn15-copd-10-2559){ref-type="table-fn"}    66±8         64±11         0.53[a](#tfn15-copd-10-2559){ref-type="table-fn"}
  Sex, n (%)                                                                                                                              
   Female                     1 (5.6)       2 (10.5)                                                           1 (8.3)      2 (8)         
   Male                       17 (94.4)     17 (89.5)                                                          11 (91.7)    23 (92)       
  BMI (kg/m^2^), mean ± SD                                                                                                                
   Baseline                   23±6          27±6          0.048[a](#tfn15-copd-10-2559){ref-type="table-fn"}   24±4         26±7          0.30[a](#tfn15-copd-10-2559){ref-type="table-fn"}
   1-year                     24±6          28±6          0.07[a](#tfn15-copd-10-2559){ref-type="table-fn"}    25±5         26±7          0.45[a](#tfn15-copd-10-2559){ref-type="table-fn"}
  FEV~1~ (mL), mean ± SD                                                                                                                  
   Baseline                   689±307       633±202       0.53[a](#tfn15-copd-10-2559){ref-type="table-fn"}    614±276      687±250       0.44[a](#tfn15-copd-10-2559){ref-type="table-fn"}
   1-year                     785±302       830±483       0.74[a](#tfn15-copd-10-2559){ref-type="table-fn"}    697±296      864±432       0.23[a](#tfn15-copd-10-2559){ref-type="table-fn"}
  PaCO~2~ (mmHg), mean ± SD                                                                                                               
   Baseline                   48±8          50±9          0.47[a](#tfn15-copd-10-2559){ref-type="table-fn"}    48±8         50±9          0.58[a](#tfn15-copd-10-2559){ref-type="table-fn"}
   1-year                     50±6          50±9          0.90[a](#tfn15-copd-10-2559){ref-type="table-fn"}    51±7         49±8          0.67[a](#tfn15-copd-10-2559){ref-type="table-fn"}
  6MWD (m), mean ± SD                                                                                                                     
   Baseline                   364±65        301±116       0.05[a](#tfn15-copd-10-2559){ref-type="table-fn"}    359±51       319±114       0.25[a](#tfn15-copd-10-2559){ref-type="table-fn"}
   1-year                     373±71        314±108       0.06[a](#tfn15-copd-10-2559){ref-type="table-fn"}    366±34       331±113       0.31[a](#tfn15-copd-10-2559){ref-type="table-fn"}
   Δ6MWD                      8.56±50.82    12.21±38.58   0.800[a](#tfn15-copd-10-2559){ref-type="table-fn"}   6.58±45.25   12.28±44.74   0.72[a](#tfn15-copd-10-2559){ref-type="table-fn"}

**Note:**

Independent sample *t*-test.

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive lung disease; FEV~1~, forced expiratory volume in 1 second; PaCO~2~, partial carbon dioxide pressure; 6MWD, 6-minute walking distance; Δ6MWD, difference between first and second 6-minute distance with 1-year interval; SD, standard deviation.

###### 

Linear regression analysis for Δ6MWD (m) with adjusted variables and COPD diagnosis as the reference

  Variable              Linear regression coefficient   95% CI            *P*-value
  --------------------- ------------------------------- ----------------- -----------
  COPD                  --                              --                --
  OHS                   −24.48                          −48.74 to −0.21   0.048
  Kyphoscoliosis        26.94                           −3.79 to 57.66    0.09
  DPLD                  16.70                           −8.51 to 41.91    0.19
  Age                   −0.80                           −1.69 to 0.08     0.07
  Male                  −4.23                           −25.45 to 17.00   0.69
  6MWD, m               −0.16                           −0.26 to 0.05     0.003
  Baseline FEV~1~, mL   0.014                           −0.005 to 0.033   0.14
  PaCO~2~ first, mmHg   0.43                            −0.53 to 1.39     0.38

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive lung disease; DPLD, diffuse parenchymal lung disease; FEV~1~, forced expiratory volume in 1 second; OHS, obesity hypoventilation syndrome; PaCO~2~, partial carbon dioxide pressure; Δ6MWD, difference between first and second 6-minute distance with 1-year interval; 6MWD, 6-minute walking distance.
